RxDoctor Payments Data

Muhammad Arshad, MD

Pain Medicine · Little Rock, ARNPI 1124068762

Payments from drug & device makers

What this record shows

This record is dominated by travel and lodging: $460 of the $644 with a category attached, or 71.4%. Boston Scientific accounts for 71.4% of it on its own, with 9 other manufacturers making up the rest. 2025 is the largest year on record at $478, more than ten times the $11 reported in 2019. That places this record below the midpoint for pain medicine clinicians in AR, where the typical reported total is $3,271.

$644in general payments, 2019–2025

Across 11 payments — averaging $58.58 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$460
  • Pfizer$31
  • BD$27
  • Collegium Pharmaceutical, Inc.$22
  • GRT US Holding, Inc.$21
  • Johnson & Johnson$20
  • plus $62 from 4 others

What the payments were for

  • Travel & lodging$46071%
  • Food & beverage$18429%

General payments by program year

19
20
21
22
23
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$644 in reported general payments places this provider in the 25th percentile of 53 pain medicine providers in Arkansas.

See all pain medicine providers in Arkansas

Medicare billing

Part B allowed, 2024
$301,463
Medicare patients
228
Services billed
6,332

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen715$17,913
OxycontinOxycodone Hcl34$16,985
Hysingla ErHydrocodone Bitartrate24$12,409
Oxycodone Hcl686$10,083
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen361$9,651
BelbucaBuprenorphine Hcl11$6,540
Lidocaine99$6,423
Oxymorphone Hcl ErOxymorphone Hcl13$5,312
Diclofenac Sodium152$4,940
Buprenorphine13$4,350
Morphine Sulfate ErMorphine Sulfate146$4,156
Naloxone Hcl52$3,351
Gabapentin266$2,592
Cyclobenzaprine Hcl177$1,906
Morphine Sulfate83$1,473

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Collegium Pharmaceutical, Inc.Belbuca$22$6,54011 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 25th percentile of 53 pain medicine providers in Arkansas.

Other pain medicine in Little Rock

See the full list for Arkansas

Where these figures come from

Is this you, or does something look wrong? →